Pump delay clouds a cleaner ICUI story
- ICUI is now more focused on Consumables and Infusion Systems after selling control of its IV Solutions business.
- Management kept 2026 guidance for adjusted EBITDA of $400M to $430M and adjusted EPS of $7.75 to $8.45.
- The key margin goal is gross margin of about 41% for fiscal 2026 as factory and logistics work pays off.
- The FDA asked for more testing data on new Medfusion and CADD pumps, delaying an important catalyst.
- Tariffs are now a two-sided issue: a possible refund from old IEEPA tariffs, but new broader tariff costs may replace it.
Cleaner, but not simple
The bull case is a cleaner ICU Medical. The Otsuka joint venture moved control of the lower-margin IV Solutions business away from ICUI, helped pay down debt, and let management spend more time on Consumables and Infusion Systems. In Q1 2026, those two core segments grew on a constant currency basis, which means growth before currency swings.
Management also reaffirmed full-year 2026 guidance: adjusted EBITDA of $400M to $430M and adjusted EPS of $7.75 to $8.45. That matters because the company now expects about $10M of higher logistics costs, but says lower tariffs and faster cost savings should offset it. The core operating target is still gross margin of about 41% for fiscal 2026.
The bear case is timing and trust. The FDA has not cleared the new Medfusion and CADD pump filings because it wants more testing data. That pushes out the main step toward resolving the April 2025 warning letter. At the same time, the tariff picture is unclear, and a lot of the cash flow improvement still depends on second-half 2026 execution.
Finn's view is balanced. This is not a broken business, but it is also not a clean win yet. The next year depends on FDA progress, tariff math, better free cash flow, and whether management finds a smart strategic outcome for parts of Vital Care.
Hospital products, long contracts
ICU Medical makes products that hospitals use to deliver drugs and fluids safely. It sells infusion consumables, oncology safety devices, infusion pumps, software tied to those pumps, and critical care products. Customers include hospitals and group purchasing organizations, which are buying groups that negotiate for many hospitals at once.
Consumables can be steady because many products are used once and replaced often. Infusion Systems are more project-based because hospitals install pumps, train staff, and then buy dedicated sets and software around the installed base. That can create sticky revenue, but it also makes installation timing important.
The IV Solutions business changed shape after the Otsuka Pharmaceutical Factory joint venture. ICUI sold a 60% interest and kept a 40% minority interest. It received cash at closing and used $200.0M to pay down part of its Term Loan A debt on May 1, 2025.
The model breaks if hospitals delay pump purchases, if the FDA slows product clearances, or if tariffs raise costs faster than ICUI can price or save its way around them.
What ICUI sells
Infusion Consumables
This includes products such as Clave needlefree connectors and SwabCap. These are repeat-use hospital supplies that support recurring demand.
Oncology Safety
ChemoLock and ChemoClave help handle cancer drugs more safely. Q1 2026 demand for Oncology products helped Consumables grow.
Infusion Pumps and Sets
The portfolio includes Plum 360, Plum Duo, Plum Solo, CADD ambulatory pumps, Medfusion syringe pumps, dedicated IV sets, and LifeShield safety software. Q1 2026 Infusion Systems revenue grew 5.8% on a constant currency basis, helped by higher large-volume pump hardware sales.
Vascular Access and Tracheostomy
Products include Jelco catheters, Port-A-Cath, and Portex tubes. These fit ICU Medical's hospital supply base rather than being a single big product bet.
IV Solutions
This includes fluids such as Sodium Chloride and Dextrose. ICUI now owns a 40% minority stake in the Otsuka joint venture after selling control of this business.
Critical Care and Pain Products
Vital Care also includes hemodynamic monitoring, anesthesia and respiratory products, temperature management, and pain management trays. Management is reviewing strategic outcomes for pieces of this portfolio.
The Q1 2026 mix
Segment mix is from the three months ended March 31, 2026. Vital Care is much smaller after the May 1, 2025 sale of control of the IV Solutions business.
What could go wrong
Medfusion and CADD FDA delay
High impact · Medium oddsICUI still needs to resolve the April 2025 FDA warning letter tied to Medfusion and CADD pumps. The FDA asked for more testing data on the new hardware submissions, so clearance is taking longer than expected. If this slips into 2027, a key overhang could stay on the stock.
Tariff refund turns into tariff cost
Medium impact · Medium oddsA February 2026 Supreme Court ruling created a possible refund for tariffs paid under IEEPA. But new broader tariff measures under Section 122 may create fresh costs. Guidance assumes these moving pieces largely offset, including about $10M of higher logistics costs.
Section 232 import tariffs
High impact · Low oddsThe U.S. Commerce Department is investigating imports of medical consumables and equipment under Section 232. ICUI says this could affect the vast majority of its product portfolio if an adverse finding leads to tariffs. That would pressure margins unless price increases or cost cuts offset it.
Second-half cash flow miss
Medium impact · Medium oddsThe free cash flow improvement story depends on integration, remediation, and restructuring cash costs easing in the second half of 2026. Infusion Systems growth is now expected to be more balanced through the year, which helps. Still, margin and cash flow targets need clean project execution.
Vital Care review disappoints
Medium impact · Medium oddsManagement is exploring different outcomes for parts of the Vital Care portfolio. A sale, partnership, or other action could unlock value, but nothing is certain. A weak deal, no deal, or lost focus could reduce the benefit of the cleaner portfolio story.
In one breath
What does ICU Medical do?
ICU Medical sells products used to deliver drugs and fluids in hospitals. Its main areas are Consumables, Infusion Systems, and Vital Care.
Why did ICU Medical sell part of IV Solutions?
ICUI sold a 60% interest in its IV Solutions business to Otsuka Pharmaceutical Factory and kept 40%. The deal helped pay down debt and shifted focus toward higher-margin core infusion products.
What is the biggest catalyst for ICUI stock?
The most important near-term catalyst is FDA clearance for the new Medfusion and CADD pump filings. That would help resolve the April 2025 warning letter overhang.
Is ICU Medical a growth company?
It is more of a turnaround and margin expansion story than a fast growth story. Q1 2026 core segments grew, but total mix changed sharply because IV Solutions moved into a joint venture.